Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Gastrointestinal Cardiovascular Clinical Trials

AVEO/Astellas 2012 filing for tivozanib as it beats Nexavar in Ph III kidney cancer trial

This article was originally published in Scrip

Executive Summary

Tivozanib, AVEO Pharmaceuticals' VEGF inhibitor partnered with Astellas Pharma, was better than Bayer HealthCare/ Onyx Pharmaceuticals ' Nexavar (sorafenib) in prolonging progression-free survival in patients with advanced renal cell carcinoma (RCC) in a Phase III head-to-head study, top-line data show. AVEO and Astellas said the trial results mean they will submit the drug for marketing approval in the US and Europe this year.

Table

View full table

Topics

Related Companies

Tags:
Gastrointestinal Cardiovascular Clinical Trials
Latest Headlines

BridgeBio Spins Out Cancer Arm With $200m Fundraise

Emergex Goes To Battle Against ‘The Nasties’

Finance Watch: Venture Rounds Trend Toward The High End

The UK’s Cancer Vaccine Partnership With BioNTech Is Another First – But Can It Deliver?

See All
UsernamePublicRestriction

Register

SC015757

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By